Rua Life Sciences Plc (RUA)
LSE 
XFRA Primary LSE Summary
Rua Life Sciences Plc (RUA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Rua Life Sciences Plc ever had a stock split?
Rua Life Sciences Plc Profile
| Life Sciences Tools & Services Industry | Healthcare Sector | - CEO | LSE Exchange | GB0033360586 ISIN |
| United Kingdom Country | 40 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
RUA Life Sciences plc represents a noteworthy entity within the medical device industry, extending its services and products across Europe, the United States, and other international markets. This conglomerate operates through a structured division that includes Biomaterials, Contract Manufacture, Vascular, and Structural Heart segments, each catering to different niches within the medical device sector. Initially founded as AorTech International plc, the organization underwent a rebranding to RUA Life Sciences plc in June 2020, marking a new era of its existence. Since its inception in 1996, the company has anchored itself firmly in Irvine, the United Kingdom, serving as a pioneer in the development and provision of critical medical device technologies and services.
Products and Services
RUA Life Sciences plc offers a comprehensive array of products and services across different domains within the medical device industry, outlined as follows:
- Biomaterials: This segment is key to the company's innovation, housing the Intellectual Property and licensing rights to an assortment of biostable and implantable polymers, such as Elast-Eon and ECSil. These materials are pivotal in the production of various medical devices, offering enhanced durability and compatibility with the human body.
- Contract Manufacture: RUA Life Sciences extends its expertise in sub-contract manufacturing, providing an array of services including manufacturing, assembly, and packing of medical devices. This segment ensures that clients receive high-quality, market-ready products through efficient and reliable service delivery.
- Vascular: Within this domain, the company specializes in the development and commercialization of polymer sealed grafts and soft tissue patches. These products are instrumental in vascular surgeries, offering solutions that significantly improve patient outcomes.
- Structural Heart: The Structural Heart segment is dedicated to the advancement of tri-leaflet polymeric heart valves. This innovation represents a significant leap forward in cardiac surgery, offering an alternative to traditional valve replacement therapies with the potential for improved longevity and performance.
